A single center observational study of the clinical characteristics and short-term outcome of 20 kidney transplant patients admitted for SARS-CoV2 pneumonia.

20 例因SARS-CoV2 肺炎入院的肾移植患者临床特征和短期预后的单中心观察性研究.

  • 影响因子:4.48
  • DOI:10.1016/j.kint.2020.04.002
  • 作者列表:"Alberici F","Delbarba E","Manenti C","Econimo L","Valerio F","Pola A","Maffei C","Possenti S","Zambetti N","Moscato M","Venturini M","Affatato S","Gaggiotti M","Bossini N","Scolari F
  • 发表时间:2020-06-01

:The outcome of SARS-CoV2 infection in patients who have received a kidney allograft and are being treated with immunosuppression is unclear. We describe 20 kidney transplant recipients (median age 59 years [inter quartile range 51-64 years], median age of transplant 13 years [9-20 years], baseline eGFR 36.5 [23-47.5]) with SARS-CoV2 induced pneumonia. At admission, all had immunosuppression withdrawn and were started on methylprednisolone 16 mg/day, all but one was commenced on antiviral therapy and hydroxychloroquine with doses adjusted for kidney function. At baseline, all patients presented fever but only one complained of difficulty in breathing. Half of patients showed chest radiographic evidence of bilateral infiltrates while the other half showed unilateral changes or no infiltrates. During a median follow-up of seven days, 87% experienced a radiological progression and among those 73% required escalation of oxygen therapy. Six patients developed acute kidney injury with one requiring hemodialysis. Six of 12 patients were treated with tocilizumab, a humanized monoclonal antibody to the IL-6 receptor. Overall, five kidney transplant recipients died after a median period of 15 days [15-19] from symptom onset. These preliminary findings describe a rapid clinical deterioration associated with chest radiographic deterioration and escalating oxygen requirement in renal transplant recipients with SARS-Cov2 pneumonia. Thus, in this limited cohort of long-term kidney transplant patients, SARS-CoV-2 induced pneumonia is characterized by high risk of progression and significant mortality.


接受同种异体肾移植并接受免疫抑制治疗的患者SARS-CoV2 感染的结局尚不清楚。我们描述了 20 例肾移植受者 (中位年龄 59 岁 [四分位距 51-64 岁],中位移植年龄 13 岁 [9-20 岁],基线eGFR 36.5 [23-47.5]) 伴SARS-CoV2 诱导肺炎。入院时,所有患者均停用免疫抑制剂,开始服用甲泼尼龙 16 mg/天,除 1 例外均开始抗病毒治疗,羟氯喹剂量调整肾功能。基线时,所有患者均出现发热,但仅有 1 例患者主诉呼吸困难。一半的患者显示胸部影像学证据显示双侧浸润,另一半显示单侧改变或无浸润。在 7 天的中位随访期间,87% 的患者出现放射学进展,其中 73% 的患者需要升级氧疗。6 例患者发生急性肾损伤,1 例需要血液透析。12 例患者中有 6 例接受了tocilizumab (一种针对IL-6 受体的人源化单克隆抗体) 治疗。总体而言,5 例肾移植受者在症状发作后中位时间为 15 天 [15-19] 后死亡。这些初步研究结果描述了与SARS-Cov2 肺炎的肾移植受者胸部影像学恶化和氧需要量增加相关的快速临床恶化。因此,在这个有限的长期肾移植患者队列中,SARS-CoV-2 诱导的肺炎具有高进展风险和显著的死亡率。



作者列表:["Lim J","Jeon S","Shin HY","Kim MJ","Seong YM","Lee WJ","Choe KW","Kang YM","Lee B","Park SJ"]

METHODS::Since mid-December of 2019, coronavirus disease 2019 (COVID-19) infection has been spreading from Wuhan, China. The confirmed COVID-19 patients in South Korea are those who came from or visited China. As secondary transmissions have occurred and the speed of transmission is accelerating, there are rising concerns about community infections. The 54-year old male is the third patient diagnosed with COVID-19 infection in Korea. He is a worker for a clothing business and had mild respiratory symptoms and intermittent fever in the beginning of hospitalization, and pneumonia symptoms on chest computerized tomography scan on day 6 of admission. This patient caused one case of secondary transmission and three cases of tertiary transmission. Hereby, we report the clinical findings of the index patient who was the first to cause tertiary transmission outside China. Interestingly, after lopinavir/ritonavir (Kaletra, AbbVie) was administered, β-coronavirus viral loads significantly decreased and no or little coronavirus titers were observed.

作者列表:["Zhang W","Du RH","Li B","Zheng XS","Yang XL","Hu B","Wang YY","Xiao GF","Yan B","Shi ZL","Zhou P"]

METHODS::In December 2019, a novel coronavirus (2019-nCoV) caused an outbreak in Wuhan, China, and soon spread to other parts of the world. It was believed that 2019-nCoV was transmitted through respiratory tract and then induced pneumonia, thus molecular diagnosis based on oral swabs was used for confirmation of this disease. Likewise, patient will be released upon two times of negative detection from oral swabs. However, many coronaviruses can also be transmitted through oral-fecal route by infecting intestines. Whether 2019-nCoV infected patients also carry virus in other organs like intestine need to be tested. We conducted investigation on patients in a local hospital who were infected with this virus. We found the presence of 2019-nCoV in anal swabs and blood as well, and more anal swab positives than oral swab positives in a later stage of infection, suggesting shedding and thereby transmitted through oral-fecal route. We also showed serology test can improve detection positive rate thus should be used in future epidemiology. Our report provides a cautionary warning that 2019-nCoV may be shed through multiple routes.

翻译标题与摘要 下载文献
作者列表:["Cheng ZJ","Shan J"]

METHODS::There is a current worldwide outbreak of a new type of coronavirus (2019-nCoV), which originated from Wuhan in China and has now spread to 17 other countries. Governments are under increased pressure to stop the outbreak spiraling into a global health emergency. At this stage, preparedness, transparency, and sharing of information are crucial to risk assessments and beginning outbreak control activities. This information should include reports from outbreak sites and from laboratories supporting the investigation. This paper aggregates and consolidates the virology, epidemiology, clinical management strategies from both English and Chinese literature, official news channels, and other official government documents. In addition, by fitting the number of infections with a single-term exponential model, we report that the infection is spreading at an exponential rate, with a doubling period of 1.8 days.